Financial Results for Quarter Ending 31 March 2025
Open PDF
| Stock | Avita Medical Inc (AVH.ASX) |
|---|---|
| Release Time | 9 May 2025, 8:25 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Avita Medical Inc Reports Q1 2025 Financial Results
Key Points
- Total revenues of $18.5 million, up 67% year-over-year
- Gross profit margin of 84.7%, up from 86.4% in Q1 2024
- Net loss of $13.9 million, an improvement from $18.7 million in Q1 2024
Full Summary
Avita Medical Inc, a regenerative medicine company, has reported its financial results for the quarter ended March 31, 2025. The company recorded total revenues of $18.5 million, up 67% from $11.1 million in the same period last year. Gross profit margin was 84.7%, compared to 86.4% in Q1 2024. Net loss was $13.9 million, an improvement from $18.7 million in the prior-year quarter. The company's sales and marketing expenses increased to $14.8 million, while general and administrative expenses decreased to $6.4 million, and research and development expenses increased to $6.3 million. Avita Medical ended the quarter with $14.9 million in cash and cash equivalents and $10.9 million in marketable securities.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In